Opendata, web and dolomites

TECNEC SIGNED

Preclinical concept validation of tumor endothelial cell metabolism for novel anti-angiogenic therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TECNEC project word cloud

Explore the words cloud of the TECNEC project. It provides you a very rough idea of what is the project "TECNEC" about.

dismissed    clinical    tumors    tecs    validate    vitro    nothing    stimulate    predict    construct    pioneering    patients    nourish    blood    anti    negative    analyze    background    block    horizons    computational    differ    followed    fundamentally    demonstrated    mice    though    manner    house    driving    screen    silico    omics    perform    biologically    knockout    sufficient    inhibition    fuelling    transcriptomic    treatment    preclinical    rank    cells    shrna    platform    inhibiting    models    promise    gems    methodology    metabolomic    normal    tumor    versus    cancer    tec    angiogenesis    deregulated    rationale    bioinformatics    angiogenic    pioneered    efficacy    treatments    inhibitors    biomex    lack    hyper    tissue    genome    validation    vivo    nec    healthy    metabolism    normalize    endothelial    novelty    promises    metabolic    main    therapy    necs    isolated    validated    data    modeling    vessel    hypothesize    genes    conditional    network    activate    hyperactive   

Project "TECNEC" data sheet

The following table provides information about the project.

Coordinator
VIB VZW 

Organization address
address: RIJVISSCHESTRAAT 120
city: ZWIJNAARDE - GENT
postcode: 9052
website: www.vib.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2022-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIB VZW BE (ZWIJNAARDE - GENT) coordinator 2˙500˙000.00

Map

 Project objective

MAIN GOAL: To characterize the metabolic changes, fuelling growth of tumor endothelial cells (TECs) versus normal healthy endothelial cells (NECs), and identify & validate metabolic genes, deregulated in TECs, as targets for anti-angiogenic cancer therapy.

BACKGROUND & RATIONALE: Tumors stimulate blood vessel growth (angiogenesis) to nourish cancer cells, but current anti-angiogenic treatments lack sufficient efficacy. NECs are widely used for anti-angiogenesis development, but TECs, the real target cells, have been dismissed, even though they differ fundamentally from NECs. We pioneered NEC metabolism research and demonstrated that inhibition of specific metabolic pathways can block angiogenesis. Nothing is however known on TEC metabolism. I hypothesize that TECs “hyper-activate” their metabolism in a tissue-specific manner, and that targeting TEC metabolism is a novel concept for inhibiting tumor angiogenesis.

METHODOLOGY: We will perform a transcriptomic and metabolomic analysis of TECs & NECs isolated from cancer patients, use an in-house developed bioinformatics platform (BIOMEX) to analyze the omics data in order to rank deregulated metabolic genes, and construct TEC-tailored genome scale metabolic network models (GEMs) allowing in silico computational modeling to predict metabolic targets that affect TEC but not NEC growth. The in vitro angiogenic activity of top targets will be biologically validated directly or after a negative selection shRNA-based screen, followed by validation in preclinical tumor models in vivo, using conditional knockout mice. All procedures are operational. Deliverables include in vivo validated metabolic targets, driving tumor angiogenesis.

NOVELTY, OVERALL & CLINICAL IMPACT: These pioneering studies on TEC metabolism promise to open up new horizons/opportunities for cancer research. Treatment with inhibitors of the validated targets promises to normalize hyperactive TEC metabolism as a novel anti-angiogenic cancer therapy.

 Publications

year authors and title journal last update
List of publications.
2018 Shawez Khan, Federico Taverna, Katerina Rohlenova, Lucas Treps, Vincent Geldhof, Laura de Rooij, Liliana Sokol, Andreas Pircher, Lena-Christin Conradi, Joanna Kalucka, Luc Schoonjans, Guy Eelen, Mieke Dewerchin, Tobias Karakach, Xuri Li, Jermaine Goveia, Peter Carmeliet
EndoDB: a database of endothelial cell transcriptomics data
published pages: D736-D744, ISSN: 0305-1048, DOI: 10.1093/nar/gky997
Nucleic Acids Research 47/D1 2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TECNEC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TECNEC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

TRUST (2018)

Truth and Semantics

Read More  

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More